Director/PDMR Shareholding

Tissue Regenix Group PLC

15 September 2023

 

Tissue Regenix Group plc

("Tissue Regenix", the "Company" or "the Group")

Director/PDMR Shareholding

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that on 15 September 2023, Brian Phillips, Non-Executive Director, bought 6,773 Ordinary Shares in the Group at a price of 54 pence per share for a total consideration of £3,657.42.

As a result, Brian Phillips holds 160,000 Ordinary Shares in the Company representing 0.23% of the total issued share capital.

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Sole Broker has changed its name to Cavendish Capital Markets Limited following completion of its own corporate merger.

For more information:

Tissue Regenix Group plc		www.tissueregenix.com
David Cocke, Chief Financial Officer		via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR)	Tel: [phone]
Alice Woodings/Lianne Applegarth	[e-mail]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Brian Phillips
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Tissue Regenix Group plc
b)	LEI	213800PNOD5UHQUFJI36
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1p each
	Identification code	GB00B5SGVL29
b)	Nature of the transaction	Purchase
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0.54	6,773
d)	Aggregated information
	- Aggregated volume	6,773
	- Price	£3,657.42
e)	Date of the transaction	15 September 2023
f)	Place of the transaction	London Stock Exchange, AIM Market

 

END